论文部分内容阅读
目的探讨肺癌患者凝血、抗凝及纤溶方面的变化。方法对３１例肺癌患者进行了凝血酶元时间（ＰＴ）、白陶土部分凝血活酶时间（ＫＰＴＴ）、纤维蛋白元定量（Ｆｂｇ）、抗凝血酶Ⅲ（ＡＴⅢ）、Ⅷ因子活性（Ⅷ：Ｃ）、Ⅷ因子相关抗原（ⅧＲ：Ａｇ）、纤溶酶元（ＰＬＧ）测定。结果肺癌患者ＰＴ、ＫＰＴＴ、ＡＴⅧ结果均正常，Ｆｂｇ３．９０±０．９１ｇ／Ｌ、Ⅷ：Ｃ（１３１．０３±２７．１１）％、ⅧＲ：Ａｇ（１４３．０７±４２．４９）％、ＰＬＧ（１９９．３１±３１．９２）ｍｇ／Ｌ。结论３１例肺癌患者Ｆｂｇ、Ⅷ：Ｃ、ⅧＲ：Ａｇ含量增高，ＰＬＧ含量减低，说明肺癌患者凝血与纤溶系统功能亢进。
Objective To investigate the changes of coagulation, anticoagulation and fibrinolysis in patients with lung cancer. Methods Thirty-one patients with lung cancer underwent prothrombin time (PT), kaolin partial thromboplastin time (KPTT), fibrinogen quantification (Fbg), antithrombin III (AT-III) and factor VIII activity ( VIII: C), VIII factor-associated antigen (VIIIR: Ag), plasminogen (PLG) assay. Results The results of PT, KPTT and AT-VIII in patients with lung cancer were all normal, Fbg 3.90±0.91g/L, VIII:C(131.03±27.11)%, VIIIR:Ag(143.07±42.49). %, PLG (199.31±31.92) mg/L. Conclusion The levels of Fbg, VIII:C and VIIIR:Ag in patients with lung cancer were increased, and the PLG content was decreased in 31 patients with lung cancer, indicating that the coagulation and fibrinolytic system in patients with lung cancer is hyperfunctional.